| Comparison of adefovir and tenofovir in the treatment of lamivudine‐resistant hepatitis B virus infection F van Bömmel, T Wünsche, S Mauss, P Reinke, A Bergk, D Schürmann, ... Hepatology 40 (6), 1421-1425, 2004 | 484 | 2004 |
| Long‐term efficacy of tenofovir monotherapy for hepatitis B virus‐monoinfected patients after failure of nucleoside/nucleotide analogues F van Bömmel, RA de Man, H Wedemeyer, K Deterding, J Petersen, ... Hepatology 51 (1), 73-80, 2010 | 435 | 2010 |
| A global scientific strategy to cure hepatitis B PA Revill, FV Chisari, JM Block, M Dandri, AJ Gehring, H Guo, J Hu, ... The lancet Gastroenterology & hepatology 4 (7), 545-558, 2019 | 423 | 2019 |
| Tenofovir for patients with lamivudine‐resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy F van Bömmel, B Zöllner, C Sarrazin, U Spengler, D Hüppe, B Möller, ... Hepatology 44 (2), 318-325, 2006 | 347 | 2006 |
| The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B GV Papatheodoridis, R Idilman, GN Dalekos, M Buti, H Chi, ... Hepatology 66 (5), 1444-1453, 2017 | 307 | 2017 |
| Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors F van Bömmel, A Bartens, A Mysickova, J Hofmann, DH Krüger, T Berg, ... Hepatology 61 (1), 66-76, 2015 | 280 | 2015 |
| Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C M Schaefer, M Schwaiger, AS Garkisch, M Pich, A Hinzpeter, ... Journal of hepatology 42 (6), 793-798, 2005 | 233 | 2005 |
| Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians P Arends, MJ Sonneveld, R Zoutendijk, I Carey, A Brown, M Fasano, ... Gut 64 (8), 1289-1295, 2015 | 227 | 2015 |
| Candidate biomarkers for the diagnosis and prognosis of drug‐induced liver injury: an international collaborative effort RJ Church, GA Kullak‐Ublick, J Aubrecht, HL Bonkovsky, N Chalasani, ... Hepatology 69 (2), 760-773, 2019 | 225 | 2019 |
| Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naive patients with a partial virological response R Zoutendijk, JGP Reijnders, A Brown, F Zoulim, D Mutimer, K Deterding, ... Hepatology 54 (2), 443-451, 2011 | 199 | 2011 |
| Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos (t) ide analogues JGP Reijnders, K Deterding, J Petersen, F Zoulim, T Santantonio, M Buti, ... Journal of hepatology 52 (4), 493-500, 2010 | 162 | 2010 |
| Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell transplantation: recommendations of the 5th European … V Mallet, F van Bömmel, C Doerig, S Pischke, O Hermine, A Locasciulli, ... The Lancet infectious diseases 16 (5), 606-617, 2016 | 142 | 2016 |
| Tenofovir treatment in patients with lamivudine‐resistant hepatitis B mutants strongly affects viral replication F van Bömmel, T Wünsche, D Schürmann, T Berg Hepatology 36 (2), 507-508, 2002 | 133 | 2002 |
| Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population GV Papatheodoridis, V Sypsa, G Dalekos, C Yurdaydin, F van Boemmel, ... Journal of hepatology 68 (6), 1129-1136, 2018 | 110 | 2018 |
| Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection G Schmutz, M Nelson, T Lutz, J Sheldon, R Bruno, F von Boemmel, ... Aids 20 (15), 1951-1954, 2006 | 99 | 2006 |
| Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B GV Papatheodoridis, V Sypsa, GN Dalekos, C Yurdaydin, F Van Boemmel, ... Journal of hepatology 72 (6), 1088-1096, 2020 | 98 | 2020 |
| Probability of HBsAg loss after nucleo (s) tide analogue withdrawal depends on HBV genotype and viral antigen levels MJ Sonneveld, SM Chiu, JY Park, SM Brakenhoff, A Kaewdech, WK Seto, ... Journal of hepatology 76 (5), 1042-1050, 2022 | 92 | 2022 |
| Host and viral factors associated with serum hepatitis B virus RNA levels among patients in need for treatment MJH van Campenhout, F van Bömmel, M Pfefferkorn, J Fischer, ... Hepatology 68 (3), 839-847, 2018 | 92 | 2018 |
| Combined effects of different interleukin-28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infection J Fischer, S Böhm, M Scholz, T Müller, H Witt, J George, C Sarrazin, ... Hepatology 55 (6), 1700-1710, 2012 | 89 | 2012 |
| Quantification of large and middle proteins of hepatitis B virus surface antigen (HBsAg) as a novel tool for the identification of inactive HBV carriers M Pfefferkorn, S Böhm, T Schott, D Deichsel, CM Bremer, K Schröder, ... Gut 67 (11), 2045-2053, 2018 | 86 | 2018 |
Christoph SarrazinVerified email at em.uni-frankfurt.de
